Part of UT Health San Antonio

 

You are here

odom_michael

Contact

210-567-5186

odom@uthscsa.edu

Programs

M.D. in Doctor of Medicine
M.S. in Clinical Investigation & Translational Science

Departments & Divisions

Department of Pediatrics
Division of Neonatal-Perinatal Medicine

Research

Researcher profile

Michael W Odom, M.D.

Professor

Department of Pediatrics of Pediatrics

I developed a reading elective for 2nd- and 3rd-year Pediatric residents to enhance their knowlege of Neonatal-Perinatal medicine. The resident is required to read a number of fundamental references and then meet with me twice weekly to discuss the assigned material. To further enhance the resident`s understanding of these readings, I developed questions and selected case studies which the resident completes prior to our meetings. This curriculum should be useful in the future both as a reading elective and for teaching sessions with residents during their rotations in the Newborn Intensive Care Unit.

Expertise: 

  • Hormonal effects on fetal lung maturation
  • Hypothermia for Hypoxic Ischemic Encephalopathy
  • Inhaled nitric oxide for newborns
  • Neonatal infectious diseases

  • Professional Background

    Education

    • 1983 - MD - Medicine - University of Texas Southwestern Medical School
    • 1979 - BA - Chemistry - Baylor University
    • Residency - Pediatrics - Vanderbilt University Medical Center
    • Postdoctoral Fellowship - Neonatal-Perinatal Medicine - Mount Zion Hospital & The Cardiovascular Research Inst, Univ of CA-San Fran
    • Postdoctoral Fellowship - Molecular Biology Training - University of Texas Health Science Center at San Antonio

    Appointments

    • 11/2009 - Community Medicine Associates, Department of Pediatrics, Division of NeonatologySan Antonio
    • 9/2007 - Professor - University of Texas Health Science Center at San Antonio, Pediatrics

  • Instruction & Training

    • 2/1996 - Present, Special Topic, The University of Texas Health Science Center

  • Research & Grants

    Research profile

    Grants

    Private

    Funding Agency Regeneron Title A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of a human monoclonal antibody, REGN 2222, for the prevention of medically attended RSV infection in preterm infants Status Active Period 11/2015 - Present Role Principal Investigator Grant Detail

  • Clinical

    Board Certifications

    • American Board of Pediatrics/Neonatal-Perinatal
    • American Board of Pediatrics